|
Saúde/Vila Real:Centro Hospitalar investe 90 milhões de euros em ... - Expresso |
... que albergará as especialidade de pneumologia, pediatria, neurologia, nefrologia (com um serviço de diálise novo) e mais uma área de internamento de ... read more |
|
Business Calendar - The Tennessean |
17, Nashville Chamber of Commerce, 211 Commerce St., Suite 100.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
. Cost: free. Page2radio "Get Connected" social networking event, ... read more |
Akela Pharma to cut costs to sustain long-term viability of the ... - Canada NewsWire (press release) |
Akela's pipeline also includes a growth hormone releasing hormone (GHRH), which is being developed for frailty and wasting in chronic renal disease. ... read more |
Dax etwas schwächer erwartet - Financial Times Deutschland |
von Jörgen Naskrent Aufgrund uneinheitlicher Vorgaben aus Übersee wird der deutsche Aktienmarkt zum Wochenstart leicht im Minus starten. ... read more |
Akela Pharma to cut costs to sustain long-term viability of the company (CNW Group via Yahoo! Finance) |
Akela Pharma Inc. , a drug development company focused on developing an inhaled fentanyl product for breakthrough cancer pain and a growth hormone releasing hormone for chronic renal disease, today announced it will be implementing measures to cut costs in order to preserve cash for its continued operations. read more |
|
|
|
<< Start < Prev 2161 2162 2163 2164 2165 2166 2167 2168 2169 2170 Next > End >>
|
Page 2170 of 2630 |